[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibacterial-agents\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibacterial-agents":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644961","interest-of-the-negative-predictive-value-of-integrons-in-the-reduction-of-large-broad-spectrum-antibiotics-consumption-for-urinary-tract-infections-100644961",false,"NCT07675018","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS: a Randomized Trial","INVICTUS","Inclusion Criteria:\n\n* Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;\n* Diagnosis of non-severe (qSOFA \\\u003C 2) urinary tract infection coupled with fever ≥ 38°C or \\\u003C 36°C\n* Presence of bacteria in the fresh urine sample and\u002For GNB on the Gram stain\n* Empirical parenteral antibiotic therapy required; Hospitalization required;\n* Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months\n* Informed consent of the patient or their representative\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Neutropenia (absolute neutrophil count \\\u003C 500 \u002F mm3)\n* Severe UTI with sepsis (qSOFA ≥ 2) or septic shock\n* Urinary derivation required (ureteral catheter\u002Fper-cutaneous nephrostomy) except for simple urinary catheterization\n* Known allergy to β-lactams\n* Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months\n* Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem\n* Not affiliated to Social Security","ALL","18 Years",{"count":20,"type":21},204,"ESTIMATED","INTERVENTIONAL",[24],"NA","Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\\\u003C2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.",[27,28,29,30],"Drug Resistance, Microbial","Biomarkers","Urinary Tract Infections (UTI's)","Antibacterial Agents",[32,33,34,35],"Integron","Antimicrobial Stewardship","Antimicrobial Resistance","Urinary Tract Infections","NOT_YET_RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":21},"2026-09-15",{"date":44,"type":21},"2028-09-21",{"name":46,"class":47},"University Hospital, Limoges","OTHER",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100572861","antimicrobial-therapy-for-difficult-to-treat-pseudomonas-aeruginosa-100572861","NCT06738771","Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study","ADDICT","Inclusion Criteria:\n\n* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy\n* Protected person (under guardianship or curatorship)\n* Persons under court protection\n* Persons deprived of liberty\n* Opposition expressed for participation in the study",{"count":58,"type":21},600,"OBSERVATIONAL","The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam\u002Fbeta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.",[62,63,64,65,30,66],"Pseudomonas Infections","Pseudomonas Aeruginosa","Prognosis","Drug Resistance, Multiple, Bacterial","Beta-lactam Antibiotics","RECRUITING","2026-04-29",{"date":70,"type":40},"2026-04-30",{"date":72,"type":40},"2025-03-11",{"date":74,"type":21},"2027-01",{"name":76,"class":47},"Centre Hospitalier Régional d'Orléans",48,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100611884","evaluation-of-a-customizable-antibiotic-stewardship-program-tailored-to-french-nursing-homes-100611884","NCT07246382","Evaluation of a Customizable Antibiotic Stewardship Program Tailored to French Nursing Homes","Evaluation of A Customizable Antibiotic Stewardship Program Based on a Comprehensive Assessment of Organizations and Health Professionals' Attitudes, and Tailored to French Nursing Homes' Needs","ORANEAT","Nursing homes\n\nInclusion criteria:\n\n• Nursing home located in one of the geographical areas participating in the study in two French regions (i.e., geographical areas covered by experts in antibiotic stewardship and\u002For in infection prevention and control who agreed to participate in the study)\n\nExclusion criteria:\n\n* Nursing home with a pharmacy for internal use\n* Participation to the pilot study\n* Data from the Health Insurance reimbursement database (Système national des données de santé) not available on the study period\n* Refusal of the nursing director to participate in the study (for Arm 1 only)\n\nResidents (Outcomes 1 to 4 and outcome 12)\n\nInclusion criteria:\n\n• Resident aged 18 or more who had lived in one of the participating nursing homes during the study period.\n\nExclusion criteria:\n\n\u002F\n\nHealthcare professionals (Outcomes 11, 13 and 15)\n\nInclusion criteria:\n\n• Healthcare professionals aged 18 or more working in one of the participating nursing homes from Arm 1 (including healthcare professionals who provide services to or collaborate with the nursing home even if they are not on-site, e.g., private general practitioners, community pharmacists, microbiologists, and professionals responsible for the implementation support).\n\nExclusion criteria:\n\n• Refusal to complete the self-administered questionnaires or to participate in qualitative investigations.",true,{"count":88,"type":21},66,[24],"To tackle antimicrobial resistance (AMR), i.e., one of the top 10 global health threats, antimicrobial stewardship (AMS) programs, i.e., coherent sets of actions promoting responsible use of antimicrobials, have been developed. Despite growing evidence about their effectiveness, their implementation remains suboptimal. Qualifying as complex interventions, these programs are prone to interactions with context, potentially compromising their successful transfer to other settings. AMR remains critical in French nursing homes (NHs). AMS programs have proven effective in reducing antimicrobial resistance in hospitals and in NHs. However, the evidence is inconsistent across studies in NHs and mostly based on North American and North European AMS programs and studies, raising concerns about transferability that might occur while implementing such AMS programs in French NHs. For instance, health systems and NH funding and organization vary considerably across countries, resulting in potential key determinants driving antibiotic use in such facilities in some countries that might remain untargeted by AMS programs developed in other countries. In addition, inconsistent effectiveness of AMS programs in NHs might also result from implementation issues, raising concerns about the strategies used to implement such programs. Based on extensive logic models linking psychosocial and organizational determinants driving antibiotic use in NHs of diverse countries, we developed and pilot-tested a customizable AMS program (i.e., the ORANEAT program) suited to French NHs, including three major components: (i) a contextual diagnostic regarding AMS in the targeted NH; (ii) based on the results of the contextual diagnostic, a bundle of tools selected from an AMS-toolkit including actions and tools suited to French NH setting; and (iii) implementation support relying on French structures involved in tackling AMR (i.e., CRAtb and CPias).\n\nThis study aims to assess the effectiveness, the sustainability, the implementation, and the transferability of the ORANEAT program in French NHs, using a mixed-method approach (quantitative and qualitative data). A cluster randomized controlled trial with two arms (ORANEAT program vs. no specific intervention) will be conducted; the cluster being the NH. The primary outcome to measure the effectiveness is total antibiotic use expressed in defined daily doses\u002F1000 resident-days\u002Fmonth.",[30],[33,93],"Nursing Homes","2025-11-17",{"date":96,"type":40},"2025-11-24",{"date":98,"type":21},"2025-12-15",{"date":100,"type":21},"2028-01-30",{"name":102,"class":47},"University of Lorraine"]